HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules

This article was originally published in The Tan Sheet

Executive Summary

FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.

You may also be interested in...



Former Food Safety Chief Doubts FDA Can Meet Foreign Inspection Mandate

The food safety law requires FDA to do more than 19,000 foreign food facility inspections in fiscal 2016, but former agency official David Acheson says, “It is not going to happen.” Acheson and other experts also question the logistics of the third-party auditor accreditation program the law established.

Guidance Underscores FDA Practice Of Letting TEAs Steep

The viability of time and extent applications as a route to market for new OTC ingredients continues to wane in light of new final guidance on the process.

Pediatric Acetaminophen Panel Debates Execution Of Dosing Changes

Pediatric OTC acetaminophen product labels should include directions for children under 2 years and as young as 6 months and instructions for dosing by weight, a panel of advisors told FDA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel